Pancreatic Cancer Clinical Trial
Official title:
Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies
The aim of the present prospective study was, first, to verify the correlation between
biliary colonization and postoperative infectious complications, and secondarily to asses
morbidity and mortality for patients who underwent pancreaticoduodenectomy.
The hypothesis is that a proportion of post-operative infections after
pancreaticoduodenectomy is due to bacteria that colonize the bile ducts during the
preoperative period.
Pancreaticoduodenectomy is part of the curative treatment of periampullary neoplasms.
Postoperative mortality for this procedure is between 1 and 5 %, and morbidity ranging from
30 to 50%. Infectious complications, with pancreatic fistula and gastric delayed empting, are
an important part of this morbidity, affecting nearly 35% of patients.
One of the risk factors of infectious complications is the presence of a preoperative
obstructive jaundice, due to obstruction of bile ducts by the tumor. In this case, it is
proposed to perform a preoperative drainage of the bile ducts, preferably by endoscopic
procedure (ERCP), associated with the placement of a endoprosthesis. However, this procedure
is controversial, this one increasing postoperative morbidity, and in particular the rate of
infectious complications. One explanation of these events is the bacteriological
contamination of the bile ducts during the endoscopic procedure. In addition, it has been
observed for the patients who have benefited from preoperative drainage, the biliary flora is
predominantly polymicrobial and may contain multiresistant nosocomial germs, unlike patients
who have not benefited from this procedure, whose biliary flora is predominantly sterile or
monomicrobial. This colonization by multiresistant germs may have consequences in the
postoperative period, in fact, up to 49% of the germs found in the bile samples are also
found in the samples taken during postoperative infectious events. This microbial release
could make it more difficult to take care of postoperative infections, with less efficacy of
conventional antibiotic treatments.
The aim of the present prospective study was, first, to verify the correlation between
biliary colonization and postoperative infectious complications, and secondarily to asses
morbidity and mortality in patients who underwent pancreaticoduodenectomy. Patients whit
colonized bile and patients with sterile bile were compared for these outcomes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
| Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
| Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
| Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
| Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|